Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

PHASE3CompletedINTERVENTIONAL

Enrollment

235

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

April 23, 2024

Study Completion Date

April 23, 2024

Conditions

Type 2 Diabetes

Interventions

DRUG

Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet

To be orally administered once daily

DRUG

Teneligliptin Placebo Oral Tablet

To be orally administered once daily

Trial Locations (1)

Seoul National University Hospital, Seoul